Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 4.3% - What's Next?

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report)'s stock price fell 4.3% during mid-day trading on Monday . The company traded as low as $12.71 and last traded at $12.65. 103,075 shares were traded during trading, a decline of 85% from the average session volume of 678,065 shares. The stock had previously closed at $13.22.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on STOK. Jefferies Financial Group began coverage on Stoke Therapeutics in a research note on Friday, July 18th. They set a "buy" rating and a $30.00 price objective on the stock. HC Wainwright cut their target price on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Needham & Company LLC reissued a "buy" rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, July 1st. Finally, Cantor Fitzgerald raised Stoke Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $25.80.

Stoke Therapeutics Stock Performance

The company has a 50-day simple moving average of $11.30 and a two-hundred day simple moving average of $9.69. The firm has a market capitalization of $737.65 million, a P/E ratio of 17.10 and a beta of 1.14.

Insiders Place Their Bets

In other news, insider Barry Ticho sold 6,471 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $10.03, for a total transaction of $64,904.13. Following the completion of the transaction, the insider directly owned 25,782 shares in the company, valued at approximately $258,593.46. This trade represents a 20.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 9.50% of the company's stock.

Hedge Funds Weigh In On Stoke Therapeutics

Several large investors have recently made changes to their positions in the business. JPMorgan Chase & Co. raised its holdings in Stoke Therapeutics by 29.2% in the 4th quarter. JPMorgan Chase & Co. now owns 19,964 shares of the company's stock worth $220,000 after acquiring an additional 4,512 shares during the last quarter. GAMMA Investing LLC grew its position in Stoke Therapeutics by 1,842.0% in the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock worth $36,000 after purchasing an additional 5,084 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Stoke Therapeutics by 123.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 95,505 shares of the company's stock worth $1,053,000 after purchasing an additional 52,813 shares during the period. Renaissance Technologies LLC bought a new stake in Stoke Therapeutics in the 4th quarter worth approximately $1,423,000. Finally, ProShare Advisors LLC bought a new stake in Stoke Therapeutics in the 4th quarter worth approximately $139,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.